Pharmacological Management of Osteoporosis in Postmenopausal Women
Key Points
Key Points
Consider bisphosphonates as the first line therapeutic choice for postmenopausal women at high risk of fracture.
Reassess fracture risk after patient has been on bisphosphonates for 3-5 years.
Following reassessment, prescribe a “bisphosphonate holiday” for women who are on bisphosphonates and are low-to-moderate risk of fracture.
Consider anabolic therapy (teriparatide or abaloparatide) for women at very high risk of fractures, including those with multiple fractures.
All women undergoing treatment with osteoporosis therapies other than anabolic therapy should consume calcium and vitamin D in their diet or via supplements.
Monitor the BMD of high-risk individuals with a low BMD every 1 to 3 years.
Treatment and Management
...ment and Management...
...ho to Tr...
...Endocrine Society (ES) recommends treating post...
Bisphosphonates...
...nopausal women at high risk of fractu...
...tmenopausal women with osteoporosis who...
...enosumab...
...postmenopausal women with osteoporosis who are a...
...postmenopausal women with osteopor...
...enopausal women with osteoporosis taking deno...
...atide and Abaloparatide...
...stmenopausal women with osteoporosis at...
4.2: In postmenopausal women with osteopo...
...mosozumab...
...menopausal women with osteoporosis at very hi...
...In postmenopausal women with osteo...
...Estrogen Receptor Modulators...
...pausal women with osteoporosis at high risk of...
...nopausal Hormone Therapy and Tibolo...
...nopausal women at high risk of fracture...
...In postmenopausal women with osteoporosis at hi...
Calcito...
...postmenopausal women at high risk of...
...m and Vitamin D...
...enopausal women with low BMD and at high...
...n postmenopausal women at high risk...
...nitoring...
...ostmenopausal women with a low BMD and at hig...
...gure 1. Algorithm for the Management o...